Aarti Pharmalabs Ltd Share Price

Overview

Aarti Pharmalabs Ltd share price is currently ₹828.91, up by ₹18.54 (2.29%) from its previous closing price of ₹810.37. The share price has gained 25.17% over the past month and gained 11.83% over the past year. The stock's 52-week low and high are ₹572.88 and ₹935.24, respectively. Aarti Pharmalabs Ltd has a market capitalisation of ₹ 7,410.00 Cr. The share price was last updated on 24 Aug 2026, 03:57 PM IST.

Aarti Pharmalabs Ltd

AARTIPHARM

₹0.00

₹18.54

2.29%

Healthcare

₹0.00(%)1D

Updated: 24 Aug 2026, 03:57:43 pm IST

Market Data

Open Price

₹829.74

Prev. Close

₹810.37

₹818.40

Day Low

₹832.41

Day High

₹572.88

52 Week Low

₹935.24

52 Week High

HealthcarePharmaceuticals & Drugs

CategoryMid Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

35.26

Sector PE

42.03

PB Ratio

3.78

Sector PB

5.82

EPS

23.51

Dividend Yield

0.67

Today's Volume

774.437 K

5 Day Avg. Volume

440.278 K

PEG Ratio

1.38

Market Cap.

₹ 7,410.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 40% at ₹2/Share	15-Sep-2026	15-Sep-2026
DividendsInterim Dividend of 30% at ₹1.5/Share	16-Feb-2026	16-Feb-2026
DividendsFinal Dividend of 50% at ₹2.5/Share	15-Sep-2025	15-Sep-2025
DividendsInterim Dividend of 50% at ₹2.5/Share	14-Feb-2025	14-Feb-2025

Mutual Fund Ownership

Mutual Fund Holder	Jun 26 Shares held	Jul 26 Shares held
UTI Healthcare Fund - Regular Plan - IDCW	1.50 Lac	1.50 Lac no change
Motilal Oswal Nifty Microcap 250 Index Fund - Regular Plan - Growth	1.41 Lac	1.37 Lac (3.05%)
WhiteOak Capital Pharma and Healthcare Fund - Regular Plan - Growth	93.46 k	1.05 Lac (11.89%)
ICICI Prudential Exports and Services Fund - Growth	1.00 Lac	86.05 k (13.95%)
ICICI Prudential Children’s Fund - Growth	74.50 k	74.50 k no change

Show all holdings

About Aarti Pharmalabs Ltd 👋

Aarti Pharmalabs Limited is engaged in the manufacturing of active pharmaceutical ingredients (APIs), advanced intermediates, and xanthine derivatives. The Company also offers comprehensive contract development and manufacturing organization (CDMO) and CMO services for drug substances and new chemical entities (NCE), including their key starting materials (KSM) and regulatory starting materials (RSM), serving various pharmaceutical companies worldwide with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of HPAPIs, corticosteroids, cytotoxic medicines, and oncology products. Its caffeine products include caffeine anhydrous, and caffeine anhydrous (granules). Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. The Company's products are exported to key regulated markets such as the United States (US), the European Union, and Japan.